The deaths due to Oral Cancer can at least be prevented theoretically. The key is to identify potential malignant lesions and prevent them from turning into oral cancer using personalized medicine, the application of pharmacogenomics to individual clinical management. Personalized medicine is rapidly impacting how medicines are discovered and tailored to individual ailments for maximum benefit. This study includes molecular docking studies of natural compounds targeting oral lichen planus which is a potentially malignant lesion. Molecular docking process involves different binding modes of ligands with the active site of the target receptor protein using the docking software Autodock4.2. Out of Ten selected compounds, it has been observed that the compounds namely Fritillebin B and Bidebiline E showed most negative binding energies against “The structure of tumor necrosis factor-alpha at 2.6 angstroms resolution. Implications for receptor binding” (1TNF) of Homo sapiens. The docking results provided better insight into the development of new drugs for oral lichen planus.